![]() ![]() Toxicity will be assessed based on the grade of the adverse events using CTCAE version 4.03. Cohort 7: Patients with EGFR or HER2 activating mutations (closed to enrollment).Cohort 6: Patients with acquired EGFR mutation who progressed while on treatment with first-line osimertinib (closed to enrollment).Cohort 5: Patients who meet the criteria for enrollment in Cohort 1 to 4, but the enrollment in the respective cohort has been closed (closed to enrollment). ![]() ![]() Cohort 4: Treatment naïve patients with HER2 exon 20 insertion mutation positive NSCLC (fully enrolled).Cohort 3: Treatment naïve patients with EGFR exon 20 insertion mutation positive NSCLC (complete).Cohort 2: Previously treated patients with HER2 exon 20 insertion mutation positive NSCLC (complete).Cohort 1: Previously treated patients with EGFR exon 20 insertion mutation positive NSCLC (complete).There will be seven patient cohorts and eligible patients will be enrolled into each cohort in parallel based on EGFR or HER2 exon 20 mutation status and prior treatment status: Eligible patients will provide written Informed Consent prior to undergoing any study procedures.Įach treatment cycle is 28 calendar days in duration. Patients must meet all Inclusion/Exclusion Criteria to participate in the study. ![]() The Screening period (Day -30 to Day -1) lasts up to approximately 30 days prior to Cycle 1, Day 1.
0 Comments
Leave a Reply. |